Navigating the New Options for the Management of Type 2 Diabetes
|
|
- Octavia Brooks
- 5 years ago
- Views:
Transcription
1 Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of Australia Medical Director, Northern Bay Health Disclosures I have previously received speaker s fees, travel support, medical writing grants or served on medical advisory committees for the following companies: Astrazeneca Australia Astrazeneca Global Boehringer-Ingelheim Australia Boehringer-Ingelheim Global Sanofi Aventis Eli-Lilly Takeda Glaxo MSD Bristol Myers Squibb Janssen Novartis NovoNordisk Primary Care Diabetes Society of Australia Diabetes Care For All By All 2 I have received no financial support from industry for the preparation of the content of this presentation Take Home Messages: Take Home Messages 2: Selecting anti diabetic medication is based on: Selecting anti diabetic medication ABCD (EFGH) Approach Consider: Individualized therapeutic targets Achieving HbA1c target while minimizing side effects, especially hypoglycaemia Individual medication risk benefit analysis: Patient preference Comorbidities and complications Drug characteristics BMI of Diabetes Considerations Glycaemic Status concern 3 4 Overview Set an A1c target - ADS guidelines Populations HbA 1c Setting an HbA1c target % SI units General 7% 53 mmol/l Diabetes of short duration and no clinical CVD Therapeutic algorithms The ABCD (EFGH) approach Case Studies Requiring lifestyle modification ± metformin 6.0% 42 mmol/l Requiring any antidiabetic agents other than metformin or insulin 6.5% 48 mmol/l Requiring insulin 7.0% 53 mmol/l Pregnancy or planning pregnancy 6% 42 mmol/l Diabetes of longer duration or clinical CVD (any therapy) 7.0% 53 mmol/l Recurrent severe hypoglycaemia or hypoglycaemia unawareness (any 8.0% 64 mmol/l therapy) Major co morbidities likely to limit life expectancy (any therapy) Symptomatic 5 1
2 Selecting the optimum HbA1c target 6% 7% 8% More stringent Approach to management of hyperglycaemia: Less stringent Patient attitude & expected treatment efforts Risks potentially associated with hypoglycaemia, other AEs Highly motivated, adherent, excellent self-care capacities Low Less motivated, non-adherent, poor self-care capacities High Disease duration Newly-diagnosed Long-standing Life expectancy Long Short Important comorbidities Absent Severe Established vascular complications Absent Severe Resources, support system Readily available Limited 7 8 Oral anti-diabetic agents and non-insulin injectables Class Generic name Brand name Biguanide Metformin Glucophage Sulfonylureas e.g. Glibenclamide (glyburide) e.g. Gliclazide e.g. Glimepiride Diabex Daonil Diamicron Amaryl α-glucosidase inhibitors Acarbose Glucobay Pioglitazone Actos DPP-4 inhibitors Saxagliptin Sitagliptin Vildagliptin Linagliptin Alogliptin Onglyza Januvia Galvus Trajenta Nesina Oral anti-diabetic agents and non-insulin injectables Class Generic name Brand name GLP-1 agonists Exenetide Exenetide Liraglutide Lixisenatide Byetta Bydureon Victoza Lyxumia Dapagliflozin Canagliflozin Empagliflozin Forxiga Invokana Jardiance 9 10 Benefits of Diabetic Medications -1 Property SU TZD DPP4i Glp1a Acarbose SGLT2i Efficacy - A1c FBG Post-prandial BG Durability of control Benefits of Diabetic Medications -2 Property SU TZD DPP4i Glp1a Acarbose SGLT2i Use in different duration of DM Convenience of dosing/delivery Early All All All All All All Injectable TDS Injectable Affordability Other benefits Rapid onset BP Improves fatty liver BP BP Empa- Reg Unlimited efficacy
3 Risks of Diabetic Medications - 1 Property SU TZD DPP4i Glp1a Acarbose SGLT2i Use with Use with Liver Failure Use/Risk in CVD Reduce dose dose dose dose dose? except Vildagliptin? (empagliflozin) Weight Gain Risks of Diabetic Medications - 2 Property SU TZD DPP4i Glp1a Acarbose SGLT2i Fractures? Heart Failure / Oedema GIT Symptoms saxagliptin? alogliptin sitagliptin (empagliflozin) Interactions Risks of Diabetic Medications - 3 Property TZD DPP4i Glp1a SGLT2i Other Possible risks? bladder cancer? pancreatitis? pancreatitis Macular oedema HR Thrush DKA Hypovolaemia Choosing 2 nd and 3 rd line agents Aim to reduce HbA1c while minimizing side effects Weight gain Depends on: Patient preference Comorbidities and complications Drug characteristics ABCD (EFGH) Approach A- Considerations 17 BMI of Diabetes Considerations Glycaemic Status concern 18 increases risks of: Hypovolaemia Cardiac failure Reduced beta cell function Osteoporosis 3
4 Range of weight change (kg) 24-May-16 B - BMI Considerations Range of weight change (kg) in response to diabetes medications C Chronic Kidney Disease more common in severe SU and dose may need to be reduced best at end stage renal failure Sulfonylureas DPP-4 Alphaglucosidase inhibitors inhibitors Diabetes medications Metformin GLP-1 receptor agonist SGLT2 Inhibitor Linagliptin needs no dose adjustment Others need dose adjustment 20 D of Diabetes E UKPDS Study showed importance of intensive glycaemic control in early years of T2DM Accord Study showed need to loosen targets in diabetes of longer duration SUs less effective with longer duration diabetes (as beta cell function declines) more risky with established CVD Empagliflozin reduced CV death by 38% over 3.s Some concerns from observational studies about CVD safety of SUs E Empa-Reg CV death F - considerations In Australia, choices limited by PBS availability more than TGA approval Most expensive to prescribe non-pbs are, and SGLT2 inhibitors
5 G Glycaemic Status Glycaemic lowering of all agents is greater at higher starting HbA1c Efficacy rating: s H Concerns s and main causes of hypoglycaemia More prevalent with and longer duration of diabetes, and SGLT2 inhibitors unlikely to cause severe hypoglycaemia and cause minimal hypoglycaemia unless used with or SU H Concerns Initial Case Avoid hypoglycaemia in these groups: Established CV disease Elderly patients Retinopathy (difficult doing SMBG) Living alone Short life expectancy unawareness Previous severe hypoglycaemia Some occupations
6 Case 3 Morbid Obesity Case 4 Older and CVD BMI year old male 1s YES empagliflozin (Jardiance)
7 Case 5 Case 6 Severe hypoglycaemia 68 year old male 68 year old male egfr 52 egfr > 60 2s (Δ dose) 2s NO (Δ dose) NO +/- +/- YES Case 7 Terminal breast cancer Take Home Messages: 78 year old female Selecting anti diabetic medication is based on: egfr > 60 3s NO Individualized therapeutic targets Achieve HbA1c target minimizing side effects, especially hypoglycaemia Individual medication risk benefit analysis Patient preference Comorbidities and complications Drug characteristics Take Home Messages 2: Thank You Selecting anti diabetic medication ABCD (EFGH) Approach BMI of Diabetes Considerations Glycaemic Status concern Any Questions:
8 Please join us at Primary Care Diabetes Society of Australia Free membership Free Online Clinical Journal including CPD modules Annual Conference Get Involved! In order to ask your question, please login now! Healthed.cnf.io 43 Primary Care Diabetes Society of Australia Diabetes Care For All By All You must have your own internet enabled device. 8
Very Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationType 2 Diabetes Mellitus hypoglycaemic agents
Type 2 Diabetes Mellitus hypoglycaemic agents Name Metformin Drug Name (eg brand name) Metformin (Diaformin Diabex) Cost / PBS per 28d mth $10.24 (1.5g dly) 1000mg+500mg / $4.44+$5.80 Concerns? Lactic
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationCurrent and future market dynamics overview
OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports MARKET DEFINITION Published diabetes reports Market definition for antidiabetic drugs Forecast
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More information3. Cardiovascular Disease?
Swiss recommendations 2016 Swiss Society of Endocrinology and Diabetology 1. Deficiency? Basal Premixed- Basal + GLP-1 RA (Xultophy ) or Basal Bolus 2. egfr < 30 ml/min? 3. Cardiovascular Disease? 4. Heart
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationPhysician Drug Reference Chart for Diabetes Antidiabetic Medications
Drug Class Compound Brand Name Mechanism of Action Advantages Disadvantages Alpha-glucosidase inhibitors Medium Cost by Bayer Healthcare, Pfizer, Takeda Research Acarbose Miglitol Voglibose Precose Glyset
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationTABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products
TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationUpdate Diabetes Therapie. Marc Y Donath
Update Diabetes Therapie Marc Y Donath Recent CV outcome studies in Diabetes N Engl J Med. 2015 373:2117-28 (Empa-Reg outcome study) N Engl J Med. 2016 June 13 (LEADER trial) N Engl J Med. 2017 June 12
More informationTYP 2 DIABETES. Marc Donath
TYP 2 DIABETES Marc Donath Treatment of Typ 2 Diabetes GLP-1 Anti-IL-1β Insulin sulfonylureas Metformin UCP-1 IL-1β Sport SGLT2i Bariatric surgery Cardiomyocytes Control Glucose Dyntar et al. Diabetes
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationDiabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015
Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD Disclosures I speak on behalf of the following companies: Astra Zeneca, Boehringer Ingelheim, Johnson & Johnson, Sanofi and
More informationDIABETES DEBATE - IS NEW BETTER?
DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief
More information28-Aug-15. RACGP guidelines 2014/15. ADS guidelines Part 1 T2D Guidelines. Part 2 What comes after metformin?
Part 1 T2D Guidelines Oral therapies in T2 diabetes Dr Gary Kilov T2D Guidelines - What s New? What comes after metformin? 1 RACGP guidelines 2014/15 ADA-EASD: Anti-Hyperglycaemic therapy 2015 3 4 Inzucchi
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationMANAGING DIABETES IN 2016 WHAT TO ADD, WHEN AND WHY?
MANAGING DIABETES IN 2016 WHAT TO ADD, WHEN AND WHY? Faculty: Maria Wolfs MD, MHSc, FRCPC Assistant Professor, University of Toronto Staff Endocrinologist, St. Michael's Hospital Relationships with commercial
More informationOral Treatments for Type 2 Diabetes. Prescribing Support Pharmacist
Oral Treatments for Type 2 Diabetes Prescribing Support Pharmacist Learning Outcomes Familiar with classes of oral hypoglycaemic agents (OHAs) used in controlling blood glucose levels When to use each
More informationTABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationMANAGING DIABETES IN 2017 WHAT TO ADD, WHEN AND WHY? December 8, 2017 Maria Wolfs MD MHSc FRCPC
MANAGING DIABETES IN 2017 WHAT TO ADD, WHEN AND WHY? December 8, 2017 Maria Wolfs MD MHSc FRCPC Faculty Disclosure Faculty: Maria Wolfs MD, MHSc, FRCPC Assistant Professor, University of Toronto Endocrinologist,
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated November 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationFebruary 2016 DIABETES PHARMACY TEAMS MAKE A DIFFERENCE. Why am I here? Why are you here? Identifying people at risk. What can we do?
DIABETES PHARMACY TEAMS MAKE A DIFFERENCE Sallianne Kavanagh MRPharmS, MSc, IP Lead Pharmacist Diabetes and Endocrinology Sheffield Teaching Hospitals UKCPA Joint Chair Diabetes and Endocrinology Why am
More informationDiabetes Mellitus case studies. Jana Vinklerová
Diabetes Mellitus case studies Jana Vinklerová Definition of diabetes (metabolic disorder) Chronically raised blood glucose (hyperglycaemia) Insulin/Glucagon Insulin is responsible for lowering glucose
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationTABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary
More informationType 2 diabetes & Cardiovascular disease. update. Barcelona, March 15th 2018
Type 2 diabetes & Cardiovascular disease update Barcelona, March 15th 2018 Francesc Xavier Cos Claramunt Sant Martí de Provençals. Head of Innovation and Health in Barcelona city Assoc.ProfUniversitatAutonomade
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationDiabetic Management of the Cardiac Patient
Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:
More informationOral Treatments. SaminaAli Prescribing Support Pharmacist
Oral Treatments for Type 2 Diabetes SaminaAli Prescribing Support Pharmacist Learning Outcomes National Guidance Familiar with classes of oral hypoglycaemic agents (OHAs) used in controlling blood glucose
More informationDiabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider:
Section #1 OBJECTIVE Diabetes Update Fall 2017 Lyle Myers BE ABLE TO DIFFERENTIATE TYPE 1 FROM TYPE 2 DIABETES Clinical features: - age at onset - body weight/bmi - family history - treatment history -
More informationWelcome to the PHASE Learning Community! October 31, 2018
Welcome to the PHASE Learning Community! October 31, 2018 Webinar Housekeeping 1. Dial in for audio: 303-248-0285, Access Code: 5617817 2. Lines are muted. You can chat in questions or unmute your line
More informationSTEP 3: Add or Substitute with one of
Prescribing of Hypoglycaemic Agents for Adult Patients with Type 2 Diabetes: Sunderland Refer to DESMOND Structured Education classes to promote Increased Physical Activity, Weight Loss and Calories Reduction
More informationDiabetes 2016: Strategies for achieving optimal diabetes control
PHASE Safety Net Community Benefit Diabetes 2016: Strategies for achieving optimal diabetes control Presented by: Lisa Gilliam, MD, PhD Clinical Leader Diabetes Program Kaiser Permanente Northern California
More informationCardiovascular Impact of Medications for Treating Type 2 Diabetes
Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational
More informationPLEASE CHECK FULL SPECIFIC PRODUCT CHARACTERISTICS FOR MORE DETAILED AND CURRENT INFORMATION:
Metformin Standard tablets Modified-release tablets Metformin 1g sachets Metformin liquid 500mg/5ml (avoid use as expensive) < 2.00 5.32 for 56 tabs 500mg 13.16 for 60 sachets > 120 Ketoacidosis General
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationDr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?
Dr Tahseen A. Chowdhury Royal London Hospital New Guidelines in Diabetes: NICE or Nasty? I have no conflicts of interest I do not undertake talks / advisory bodies / research for any pharma company Consultant
More informationDisclaimers 22/03/2018. Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2
Disclaimers Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2 I have not received money or gifts from medical device companies or from the pharmaceutical
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationNewer Therapies for Type 2 Diabetes
Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationDr Karen McNeil Consultant Endocrinologist
Dr Karen McNeil Consultant Endocrinologist Aged 53 Type 2 Diabetes 2010 HbA1c 7.9% ACR 5.3 mg/mmol What treatment? MF 500 mg bd (misses midday dose) Control Symptoms, BGL Complications DR, DN, PN Associations
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationSIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION
SIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION DR ROSE ZHAO-WEI TING ( 丁昭慧醫生 ) MBBS (HK), MRCP (UK), FHKCP, FHKAM (MEDICINE) Specialist in Endocrinology, Diabetes and Metabolism
More informationManaging Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University
Managing Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University Objectives: By the end of this session, you will be able to: Identify
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationDisclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017
Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials Shannon Wakeley MD Complete Endocrinology 9/2/2017 Disclosures Speakers Bureau: Astra Zeneca, Sanofi, Abbvie, Boehringer-Ingelheim, Medtronic,
More informationClinical Cases in Diabetes Management. Joseph Cook D.O.
Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians
More information4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis
HOW TO REGULATE DIABETES MEDICATIONS By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE Diagnosis 1 NORMAL BODY The normal pancreas releases one unit of insulin every hour all day. The normal pancreas
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationDisclosures of Interest. Publications Diabetologia Key points to emphasize
Disclosures of Interest No conflicts or disclosures How to Use the American Diabetes Association s Type 2 Diabetes Treatment Algorithm Rashida Downing, MD, FAAFP Primary Care Physician JenCare Medical
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationQuick Reference Guide
2018 Clinical Practice Guidelines Quick Reference Guide 416569-18 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Screening and diagnosis of type 2 diabetes in adults Assess risk factors for
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationObjectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Choosing the Right Agent for your Patient with diabetes: Individualizing type 2 diabetes management in light of the expanding therapies
More informationDIABETES UPDATE 2018
DIABETES UPDATE 2018 Jerome V. Tolbert, M.D., Ph.D. Assistant Professor of Medicine Icahn School of Medicine at Mt. Sinai Division of Endocrinology and Bone Diseases 317 East 17 th Street New York, New
More informationIntensification of Diabetic Therapy. Case studies
Intensification of Diabetic Therapy Case studies Patient #1 1 st visit: 64 year old male, H/O prediabetes, lost weight 280 lbs. to 240 lbs. ER for dental abscess, glucose >300 A1C 11.4%, no diabetic medication,
More informationMANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes
National Institute for Health and Care Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes Response to consultee and commentator
More informationDate of Review: September 2016 Date of Last Review: September 2015
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationArrange 3 Monthly Review Re-enforce LIFESTYLE advice and check DRUG COMPLIANCE at each visit Target HbA1c < 53mmol/mol
Prescribing of Hypoglycaemic Agents for Adult Patients with Type 2 Diabetes: Sunderland Refer to DESMOND Structured Education classes to promote Increased Physical Activity, Weight Loss and Calories Reduction
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationDiabetes Update: Keeping patients safe. Victoria Ruszala MFRPSII North Bristol NHS Trust
Diabetes Update: Keeping patients safe Victoria Ruszala MFRPSII North Bristol NHS Trust Declaration of Interests I have received funding from the following companies for providing education sessions, attending
More informationType 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18
Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18 No conflicts of interest Objectives for this talk Update on non-insulin drug therapy fro type 2 DM Appropriate use of insulin in type 2 DM ADA
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationNew Antidiabetic Medications
New Antidiabetic Medications A/Prof Harvey Newnham Director of General Medicine Clinical Program Director Emergency and Acute Medicine, Alfred Health, Melbourne 5 th May 2013 Diagnosed Diabetes USA Adults
More informationMr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)
Dr David Kim Endocrinologist and General Physician Waitemata DHB and Apollo Specialist Clinic Albany Auckland Mr Rab Burtun Diabetes Nurse Specialist Waitemata DHB Waitakere Hospital Auckland 8:30-10:30
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationIpoglicemia: trattamento e strategie di prevenzione
Ipoglicemia: trattamento e strategie di prevenzione Antonio Ceriello Insititut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain Frequency of Hypoglycemia Increases as HbA1c Declines
More informationCASES DR TINA KADER MCGILL JGH; LMC CVPH CDE
CASES DR TINA KADER MCGILL JGH; LMC CVPH CDE Faculty/Presenter Disclosure Faculty/Presenter: tina kader Relationships with commercial interests: Grants/research support: BI; Sanofi Speaker s bureau/honoraria:
More informationDiabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018
Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding
More informationMaking Sense of New DM Therapies and Technologies
Making Sense of New DM Therapies and Technologies Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationNew Therapies for Diabetes
Type 2 diabetes is increasingly prevalent New Therapies for Diabetes Lynn Mack, M.D. Associate Professor Diabetes, Endocrinology, & Metabolism The Nebraska Medical Center lmack@unmc.edu No Conflicts of
More information